Buscar
Edwards Lifesciences Corp
EWAñadir a la lista de seguimiento
87.360USD
+0.680+0.78%
Cierre 06/18, 16:00（ET）Cotizaciones retrasadas 15 min
50.30BCap. mercado
46.39P/E TTM
Más Datos de Edwards Lifesciences Corp Compañía
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
Información de Edwards Lifesciences Corp
Símbolo de cotizaciónEW
Nombre de la empresaEdwards Lifesciences Corp
Fecha de salida a bolsaMar 27, 2000
Director ejecutivoZovighian (Bernard J)
Número de empleados15800
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 27
DirecciónOne Edwards Way
CiudadIRVINE
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal92614
Teléfono19492502500
Sitio Webhttps://www.edwards.com
Símbolo de cotizaciónEW
Fecha de salida a bolsaMar 27, 2000
Director ejecutivoZovighian (Bernard J)
Ejecutivos de Edwards Lifesciences Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Scott B. Ullem
Mr. Scott B. Ullem
Chief Financial Officer, Corporate Vice President
Chief Financial Officer, Corporate Vice President
284.40K
+2.48%
Mr. Steven R. (Steve) Loranger
Mr. Steven R. (Steve) Loranger
Independent Director
Independent Director
79.69K
+5.41%
Mr. Daniel J. Lippis
Mr. Daniel J. Lippis
Corporate Vice President - Transcatheter Aortic Valve Replacement
Corporate Vice President - Transcatheter Aortic Valve Replacement
39.67K
+16.33%
Mr. Bernard J. Zovighian
Mr. Bernard J. Zovighian
Chief Executive Officer, Director
Chief Executive Officer, Director
30.12K
+59.32%
Mr. Daveen Chopra
Mr. Daveen Chopra
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
22.62K
+53.60%
Dr. David T. Feinberg, M.D.
Dr. David T. Feinberg, M.D.
Independent Director
Independent Director
5.56K
+58.48%
Mr. Donald E. Bobo, Jr.
Mr. Donald E. Bobo, Jr.
Corporate Vice President - Strategy and Corporate Development
Corporate Vice President - Strategy and Corporate Development
--
--
Mr. Nicholas J. (Nick) Valeriani
Mr. Nicholas J. (Nick) Valeriani
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Kieran T. Gallahue
Mr. Kieran T. Gallahue
Independent Director
Independent Director
--
--
Ms. Leslie S. Heisz
Ms. Leslie S. Heisz
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Scott B. Ullem
Mr. Scott B. Ullem
Chief Financial Officer, Corporate Vice President
Chief Financial Officer, Corporate Vice President
284.40K
+2.48%
Mr. Steven R. (Steve) Loranger
Mr. Steven R. (Steve) Loranger
Independent Director
Independent Director
79.69K
+5.41%
Mr. Daniel J. Lippis
Mr. Daniel J. Lippis
Corporate Vice President - Transcatheter Aortic Valve Replacement
Corporate Vice President - Transcatheter Aortic Valve Replacement
39.67K
+16.33%
Mr. Bernard J. Zovighian
Mr. Bernard J. Zovighian
Chief Executive Officer, Director
Chief Executive Officer, Director
30.12K
+59.32%
Mr. Daveen Chopra
Mr. Daveen Chopra
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
22.62K
+53.60%
Dr. David T. Feinberg, M.D.
Dr. David T. Feinberg, M.D.
Independent Director
Independent Director
5.56K
+58.48%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Edwards Lifesciences Corp?
Los cinco principales accionistas de Edwards Lifesciences Corp son: Mr. Scott B. Ullem
¿Cuántas instituciones poseen acciones de Edwards Lifesciences Corp (EW)?
A fecha de 2026Q1, 2620 instituciones poseen acciones de Edwards Lifesciences Corp, con un valor de mercado combinado de aproximadamente 539.60M, lo que representa el 93.71% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -12944884.00.
¿Cuál es la mayor fuente de ganancias de Edwards Lifesciences Corp?
El 2026Q1, el segmento empresarial Transcatheter Aortic Valve Replacement generó la ganancia más alta para Edwards Lifesciences Corp, ascendiendo a 4.49B y representando el 73.96% de la ganancia total.
